Merz Neurosciences to Present XEOMIN® (IncobotulinumtoxinA) Data at the 21st International Congress of Parkinson’s Disease and Movement Disorders

Merz to Present Five Posters Including Late Breaker

RALEIGH, N.C.--()--Merz Neurosciences, a division of Merz North America, announced today that it will present a late breaking poster and four additional poster presentations at the 21st International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Vancouver, BC taking place from June 4-8, 2017.

The breadth of data to be presented is encouraging and provides valuable information to the scientific and medical communities. The results will deepen understanding of the complexities of treating, and the challenges of living with, neurological disorders,” said Bob Rhatigan, President and CEO of Merz North America. “We are committed to ongoing research that can ultimately help patients by providing new treatment options to address the unique needs of patients suffering from neurologic, movement and spasticity disorders.”

On Wednesday, June 7, the following Late-Breaking & Study Group Abstract Poster will be presented in Ballroom D of the Vancouver Convention Centre – WEST from 1:15 p.m. until 2:45 p.m. (PT) and will be displayed for the entire duration of the Scientific Program (Monday, June 5 – Thursday, June 8).

  • SIAXI: Efficacy and safety of incobotulinumtoxinA for the treatment of sialorrhea in Parkinson’s disease (PD) and other neurological conditions: Results of a Phase III, placebo-controlled, randomized, double-blind study. Andrew Blitzer, MD, DDS - Columbia University College of Physicians and Surgeons; Icahn School of Medicine at Mt. Sinai; NY Center for Voice and Swallowing Disorders, New York, NY, USA. Poster # LBA28.

The following four posters will be presented in Exhibit Hall C of the Vancouver Convention Centre – WEST from 1:15 p.m. until 2:45 p.m. (PT) and will be available for viewing from 9:00 a.m. until 5:00 p.m. on the day of presentation only.

  • Wednesday, June 7: Efficacy of incobotulinumtoxinA in treatment of lower limb spasticity in adults. David M Simpson, MD, FAAN – Icahn School of Medicine at Mount Sinai, NY, USA. Poster #1151.
  • Wednesday, June 7: Efficacy of incobotulinumtoxinA for the treatment of shoulder spasticity. David M Simpson, MD, FAAN – Icahn School of Medicine at Mount Sinai, NY, USA. Poster #1152.
  • Thursday, June 8: Efficacy and safety of incobotulinumtoxinA (inco/A) for essential tremor using kinematics-guided clinical decision support: A randomized, double-blind, placebo-controlled trial. Mandar Jog, MD – Lawson Health Research Institute, London, ON, Canada. Poster #1173.
  • Thursday, June 8: Cost-utility analysis of flexible interval incobotulinumtoxinA versus onabotulinumtoxinA in the management of blepharospasm and cervical dystonia in Ontario, Canada. Marie-Eve Gendron, PhD – Merz Pharma Canada, Burlington, ON, Canada. Poster #1196.

Merz is also pleased to be supporting the following Educational Sessions:

  • Plenary Session (#1102 Treatment of Dystonia) on Sunday, June 4 from 11:00 a.m. – 1p.m. (PT) in Ballroom A of the Vancouver Convention Centre – West;
  • Skills Workshop (#2412 Which Targeting Technique for Botulinum Toxin Injections?) on Monday, June 5, 6:00 p.m. –7:30 p.m. (PT) in Room 204 of the Vancouver Convention Centre – West; and
  • Teaching Course (#3310 Classification, Pathogenesis, and Management of Dystonia) on Tuesday, June 6 from 3:30 p.m. (PT) – 5:30 (p.m.) PT in Room 219 of the Vancouver Convention Centre – West.

For more information, please see XEOMIN full Prescribing Information and Medication Guide.

About XEOMIN® (incobotulinumtoxinA)

XEOMIN® (incobotulinumtoxinA) is a prescription medicine that is injected into muscles and used to treat increased muscle stiffness in the arm of adults with upper limb spasticity, the abnormal head position and neck pain that happens with cervical dystonia (CD) in adults, and to treat abnormal spasm of the eyelids (blepharospasm) in adults who have had prior treatment with onabotulinumtoxinA (Botox®).

To learn more about Merz Neurosciences and their U.S. product portfolio, please visit www.merzusa.com/neurosciences.

XEOMIN® IMPORTANT CONSUMER SAFETY INFORMATION

Read the Medication Guide before you start receiving XEOMIN® (Zeo-min) and each time XEOMIN® is given to you as there may be new information. The risk information provided here is not comprehensive. To learn more:

  • Talk to your health care provider or pharmacist
  • Visit www.xeomin.com to obtain the FDA-approved product labeling
  • Call 1-888-4-XEOMIN

Uses XEOMIN® is a prescription medicine that is injected into muscles and used to treat:

  • increased muscle stiffness in the arm of adults with upper limb spasticity
  • abnormal head position and neck pain in adults with cervical dystonia (CD)
  • abnormal spasm of the eyelids (blepharospasm) in adults who have had prior treatment with onabotulinumtoxinA (BOTOX®)

It is not known whether XEOMIN® is safe or effective in children.

Warnings

XEOMIN® may cause serious side effects that can be life threatening. Call your doctor or get medical help right away if you have any of these problems anytime (hours to weeks) after treatment with XEOMIN®:

  • Problems with swallowing, speaking, or breathing can happen within hours to weeks after an injection of XEOMIN® if the muscles that you use to breathe and swallow become weak. Death can happen as a complication if you have severe problems with swallowing or breathing after treatment with XEOMIN®.
  • People with certain breathing problems may need to use muscles in their neck to help them breathe and may be at greater risk for serious breathing problems with XEOMIN®.
  • Swallowing problems may last for several months, and during that time you may need a feeding tube to receive food and water. If swallowing problems are severe, food or liquids may go into your lungs. People who already have swallowing or breathing problems before receiving XEOMIN® have the highest risk of getting these problems.
  • Spread of toxin effects. In some cases, the effect of botulinum toxin may affect areas of the body away from the injection site and cause symptoms of a serious condition called botulism. The symptoms of botulism include: loss of strength and muscle weakness all over the body, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, trouble swallowing.

These problems could make it unsafe for you to drive a car or do other dangerous activities.

Do not take XEOMIN® if you: are allergic to XEOMIN® or any of the ingredients in XEOMIN® (see the end of this Guide for a list of ingredients in XEOMIN®), had an allergic reaction to any other botulinum toxin product such as rimabotulinumtoxinB (Myobloc®), onabotulinumtoxinA (Botox®, Botox® Cosmetic), or abobotulinumtoxinA (Dysport®) or have a skin infection at the planned injection site.

Ask a doctor before use if you

  • have a disease that affects your muscles and nerves (such as amyotrophic lateral sclerosis [ALS or Lou Gehrig's disease], myasthenia gravis or Lambert-Eaton syndrome)
  • have had any side effect from any other botulinum toxin in the past
  • have a breathing problem such as asthma or emphysema
  • have a history of swallowing problems or inhaling food or fluid into your lungs (aspiration)
  • have bleeding problems
  • have drooping eyelids
  • have plans to have surgery
  • have had surgery on your face
  • are pregnant or plan to become pregnant. It is not known if XEOMIN® can harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if XEOMIN® passes into breast milk.

Tell your doctor about all of your medical conditions and all of the medicines you take, including: prescription and over-the-counter medicines, vitamins and herbal supplements. Using XEOMIN® with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received XEOMIN in the past.

Especially tell your doctor if you:

  • have received any other botulinum toxin product in the last four months
  • have received injections of botulinum toxin such as rimabotulinumtoxinB (MYOBLOC®), onabotulinumtoxinA (BOTOX®, BOTOX® COSMETIC) and abobotulinumtoxinA (DYSPORT®) in the past. Be sure your doctor knows exactly which product you received. The dose of XEOMIN® may be different
  • from other botulinum toxin products that you have received.
  • have recently received an antibiotic by injection
  • take muscle relaxants
  • take an allergy or cold medicine
  • take a sleep medicine
  • take a blood thinner medicine

Ask your doctor if you are not sure if your medicine is one that is listed above.

Possible Side Effects

XEOMIN® can cause serious side effects that can be life threatening. See “Warnings.”

The most common side effects of XEOMIN® include:

  • dry mouth
  • discomfort or pain at the injection site
  • tiredness
  • headache
  • neck pain
  • muscle weakness
  • eye problems, including double vision, blurred vision, drooping eyelids, swelling of your eyelids, and dry eyes. Reduced blinking can also occur. Tell your doctor or get medical help right away if you have eye pain or irritation following treatment.

XEOMIN® may cause other serious side effects including allergic reactions. Symptoms of an allergic reaction to XEOMIN® may include: itching, rash, redness, swelling, wheezing, asthma symptoms, dizziness or feeling faint. Tell your doctor or get medical help right away if you have wheezing or asthma symptoms, or if you get dizzy or faint. These are not all the possible side effects of XEOMIN®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Directions

  • XEOMIN® is a shot (injection) that your doctor will give you.
  • XEOMIN® is injected into your affected muscles.
  • Your doctor may change your dose of XEOMIN® until you and your doctor find the best dose for you.

General information about the safe and effective use of XEOMIN

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use XEOMIN for a condition for which it was not prescribed. Do not give XEOMIN to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or doctor for information about XEOMIN that is written for health professionals.

Active Ingredient: incobotulinumtoxinA

Inactive Ingredients: human albumin and sucrose

Copyright © 2016 Merz North America, Inc. All rights reserved. MERZ, the MERZ logo, and XEOMIN are registered trademarks of Merz Pharma GmbH & Co. KgaA. Botox, Dysport and Myobloc are registered trademarks of their respective owners.

For more information, please see XEOMIN full Prescribing Information and Medication Guide.

About Merz Neurosciences

Merz Neurosciences is a division of Merz North America and is deeply committed to offering novel therapeutic options that address the largely unmet medical needs that exist within the area of neuroscience. Merz Neurosciences is an important contributor to the U.S. neurosciences space and offers a portfolio that includes the neurotoxin Xeomin® (incobotulinumtoxinA), the anticholinergic Cuvposa® (glycopyrrolate) Oral Solution and the Prolaryn® injectable implant family of products. To learn more about Merz Neurosciences and their U.S. product portfolio, please visit www.merzusa.com/neurosciences.

About Merz North America

Merz North America is a specialty healthcare company dedicated to the development and marketing of innovative quality products for physicians and patients across the United States and Canada. Merz products are distributed through two divisions, Aesthetics and Neurosciences, and are developed with the goal of improving patients’ health and quality of life by delivering therapies that bring about real progress. Merz North America is a privately-held company based in Raleigh, North Carolina. To learn more about Merz North America, please visit www.merzusa.com.

Contacts

Merz North America
Emily Browder, 919-582-8114
Corporate Communications
Emily.browder@merz.com

Recent Stories

RSS feed for Merz North America